Evidence map›Paper›PMID 32804353›Full record

ArticleJournal of cancer survivorship : research and practice2021

How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support.

Maurice J Berkowitz, Carlie K Thompson, Laura T Zibecchi, Minna K Lee, Elani Streja, Jacob S Berkowitz, Cachet M Wenziger, Jennifer L Baker, Maggie L DiNome, Deanna J Attai

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Genomic and Biologic Landscapes of Breast Cancer and Racial Differences.International journal of molecular sciences · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Maurice J BerkowitzDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Carlie K ThompsonDepartment of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Laura T ZibecchiDepartment of Nursing, University of California Los Angeles, Los Angeles, USA.
Minna K LeeDepartment of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Elani StrejaDepartment of Medicine, University of California Irvine School of Medicine, Irvine, USA.
Jacob S BerkowitzDietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, USA.
Cachet M WenzigerDepartment of Medicine, University of California Irvine School of Medicine, Irvine, USA.
Jennifer L BakerDepartment of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Maggie L DiNomeDepartment of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Deanna J AttaiDepartment of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA. dattai@mednet.ucla.edu.ORCID 0000-0002-1893-1183
University of California, Los Angeles · USUniversity of California, Irvine · USUniversity of Pittsburgh · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMany patients with hormone receptor-positive (HR+) breast cancer do not adhere to endocrine therapy (ET), and treatment-related side effects are often discussed by participants in online breast cancer forums. Our aim was to survey this unique group of patients about their ET-related experiences.

methodsWe partnered with patients active in breast cancer social media communities to develop a survey assessing ET-related side effects and medical team communication. Patients with a history of HR+ breast cancer who had received a recommendation to take ET were eligible to participate in the anonymous, online survey.

resultsRespondents included 2353 women and 54 men. Aromatase inhibitors were the most commonly used medication. Side effects were reported by 91.2%, were more often experienced by women than men (p < 0.001), and were primarily related to medication type. Approximately one-third of respondents discontinued therapy early. While most felt supported by their medical team, 31.5% reported that their side effects were dismissed or minimized. Survey respondents most frequently reported that a healthy diet and exercise, yoga/acupuncture, and vitamins/supplements were helpful in managing ET-related side effects.

conclusionsET-related side effects are very common, and one-third discontinued treatment early. Lifestyle changes and complementary therapies can be important tools for side effect management. One-third of patients did not feel that their side effects were taken seriously. IMPLICATIONS FOR CANCER SURVIVORS: This is the largest survey of ET use by participants in online breast cancer communities. Further research is needed to identify strategies to improve treatment adherence and to better manage ET-related side effects.

Indexed as

Breast NeoplasmsAntineoplastic Agents, HormonalAromatase InhibitorsChemotherapy, AdjuvantFemaleHumansMaleMedication AdherenceMiddle AgedSurveys and QuestionnairesTamoxifenAntineoplastic Agents, HormonalAromatase InhibitorsTamoxifenAromatase inhibitorsBreast cancerEndocrine therapySide effectsTamoxifen

Identifiers

PMID32804353
PMCPMC7430212
OpenAlexW3049723141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.